For Investors

Many mental health apps claim to be “evidence-based” simply because they reference cognitive behaviour therapy (CBT) or other forms of therapy, but they do not prove effectiveness across diverse populations. TheraVerse goes further... built on a rigorous clinical validation framework, tested and trialed in Malaysia & Southeast Asia to ensure cultural relevance and measurable outcomes. This combination of scientific rigor and local validation creates a differentiated digital therapeutic (DTx) / software as medical device (SaMD) pathway that global mental health apps cannot replicate.

Our team combines the rigour of established biopharma with the agility of a startup. We unite all the critical functions, from psychiatric expertise to market access and legal know-how, to pursue one clear objective: delivering a trusted DTx mental health solution with real market reach. By channelling this collective rigour, we are raising the bar for DTx and paving the way toward a deeptech and neurotech future.